Q-omics provides the consensus-scored RNF152 profile across patient tissues and cancer cell-line models. RNF152 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF152 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RNF152 RNA expression shows 19,555 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where RNF152 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF152 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF152 survival associations across molecular data types. RNF152 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF152 RNA expression–survival associations across cancer types. High RNF152 expression shows unfavorable associations in UVM, ACC and STAD, but favorable associations in KIRC, ESCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF152 RNA expression.
This table summarizes RNF152 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF152. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF152 shows lower tumor expression in COAD, KIRC, KIRP, LIHC and READ and higher tumor expression in HNSC. The COAD box plot shows higher RNF152 RNA expression in normal versus tumor tissue (log2 FC = −2.996, t-test p < 0.001).
This table shows molecular features associated with RNF152 in patient tissues and cancer cell lines. In patient samples, RNF152 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF152 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
